Thomas Taapken, a senior manager with venture capital experience, has been named chief financial officer, effective 1 October, of InflaRx NV in Germany as the company starts a Phase 3 trial of its lead product for inflammatory diseases. He joins InflaRx from the Belgian immunotherapy company Imcyse SA. He has also been CFO of Medigene AG and both CEO and CFO of Epigenomics AG. Dr Taapken holds a PhD in organic chemistry from the Technical University of Berlin and studied economics and physics at the University of Göttingen.
Separately, InflaRx announced the promotion of Jordan Zwick, head of business development, to the new position of chief strategy officer with responsibility for US operations.
InflaRx announced the appointments on 17 September 2020.
Copyright 2020 Evernow Publishing Ltd